High dose rate intraluminal brachytherapy in the treatment of malignant airway obstructions.
Endobronchial brachytherapy has been increasingly used in an effort to improve local control and relieve symptoms of malignant airway obstructions. Results of the high dose rate (HDR) intraluminal brachytherapy in 67 patients with inoperable endobronchial tumor treated by combination of teletherapy and brachytherapy with curative (group A ) or palliative (group B) intent, patients with recurrent tumors after previous radiotherapy treated by endobronchial brachytherapy alone (group C), and patients treated by brachytherapy without teletherapy (group D) are presented. Symptomatic improvement was achieved in 66%, 74%, 64% and bronchoscopic response in 70%, 85%, 78% of patients in groups A, B and C, respectively. Median survival was 365, 242 and 884 days from diagnosis and 245, 151 and 153 days from the first brachytherapy application in groups A, B and C, respectively. In group D complete bronchoscopic response was achieved in 3 of 4 patients with early tumor and partial response in 6 of 7 patients with advanced disease. We observed 4 acute and 9 late complications. Brachytherapy is an effective palliative treatment of malignant airway stenosis, but the effect on survival is not apparent.
Petera
J
J
Department of Oncology and Radiotherapy, Charles University Medical School Teaching Hospital, Hradec Králové, Czech Republic. petera@fnhk.cz
Spásová
I
I
Neumanová
R
R
Skricková
J
J
Salajka
F
F
Hrazdírová
A
A
Kaplanová
J
J
Coupková
H
H
Coupek
P
P
Kucera
M
M
D000230:Adenocarcinoma / Q000150:complications / Q000401:mortality / Q000532:radiotherapy; D000368:Aged; D000402:Airway Obstruction / Q000209:etiology / Q000532:radiotherapy*; D001918:Brachytherapy / Q000379:methods; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000401:mortality / Q000532:radiotherapy; D018288:Carcinoma, Small Cell / Q000150:complications / Q000401:mortality / Q000532:radiotherapy; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000401:mortality / Q000532:radiotherapy; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000150:complications / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010166:Palliative Care; D011879:Radiotherapy Dosage; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome